An Evolution in Name, Structure, and Strategy Reflecting the Company’s AI-Driven Platform and Bio-Native Discovery Vision
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), ImmunoPrecise Antibodies Ltd. and its subsidiaries (BioStrand and Talem) today announced a unification under a single corporate brand, MindWalk, and a change of its Nasdaq ticker symbol to HYFT. The new identity conveys the Company’s evolution into a Bio-Native AI platform business built at the intersection of AI, multi-omics data, and advanced laboratory research.
“Today is an evolutionary step forward,”said Dr. Jennifer Bath, President and Chief Executive Officer of MindWalk. “Inspired by Darwin’s thinking path, MindWalk is about seeing what others can’t—patterns hidden in biology that point to better medicines. Our role is to convert that insight into impact, uniting science, computation, and responsible experimentation to change the pace of care.”
MindWalk: A New Era in Bio-Native AI-Powered Discovery
Inspired by Charles Darwin’s daily walks along his “thinking path” — where he questioned convention and advanced new theories — MindWalk carries that spirit forward. It represents a modern extension of that philosophy: a transformative, pattern-seeking journey through the complexity of biology, powered by the combined strengths of AI, data and advanced lab research.
Now operating as a Bio-Native AI company, MindWalk reimagines discovery by intelligently integrating data across formats and disciplines—turning information into dynamic biological meaning. By making biological diversity computable, MindWalk unifies this data into a single, structured system that accelerates discovery with depth and direction.
At the core of this transformation is the Company’s LensAI™ platform powered by HYFT® technology, built to redefine how biologics are discovered and developed. Drug discovery, unified—from idea to impact. This brand evolution is also a business transformation. MindWalk is expanding beyond specialized wet-lab services to commercialize an intelligence-platform model—amplifying discovery, enabling recurring SaaS offerings, creating generative asset opportunities, and supporting scalable partnerships across the pharmaceutical ecosystem.
Key Business Highlights:
- Unified Brand Identity: ImmunoPrecise Antibodies (IPA) together with its subsidiaries BioStrand and Talem are now unified as MindWalk, a single brand under the umbrella of MindWalk Holdings Corp.
- Business Model Shift: Transitioning from standalone wet-lab services to an integrated, scalable platform company model — launching DaaS, SaaS offerings, enhancing asset generation, and enabling large-scale partnerships
- New Nasdaq Ticker: “HYFT” — replacing “IPA” to reflect the foundational role of HYFT® technology in the company’s AI stack
“MindWalk is the first to make biological diversity truly computable — integrating multi-modal data into a structured system that drives insight with clarity, speed, and depth,” added Dr. Bath.
For more information visit: mindwalkAI.com
Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!